Neuland Laboratories shares rally 7% as profit jumps seven-fold and revenue doubles in Q4

Shares of Neuland Laboratories surged as much as 7.65% to hit an intraday high of Rs 18,305 in Wednesday’s trading session after the company posted a blockbuster Q4 performance, driven by sharp growth in both profit and revenue on a year-on-year basis.

The pharmaceutical company reported a massive 660% jump in consolidated net profit to Rs 213 crore for Q4FY26, compared to Rs 28 crore in the corresponding quarter last year.

Consolidated revenue more than doubled, soaring 136% YoY to Rs 776.3 crore from Rs 328.4 crore in Q4FY25, reflecting strong business momentum across key segments.

Operating performance also remained robust, with EBITDA skyrocketing to Rs 319 crore in Q4FY26 from Rs 58 crore a year ago, highlighting significant margin expansion and operational efficiency.

For the full financial year FY26, Neuland Laboratories reported total income of Rs 2,053.1 crore, while EBITDA stood at Rs 603.4 crore.

Commenting on the company’s performance, Saharsh Davuluri, Chief Executive Officer and Managing Director, said the company ended FY26 on a strong note in line with its expectations, supported by healthy business visibility in the short to medium term driven by commercial and near-commercial molecules. He added that Neuland continues to focus on execution discipline, customer satisfaction, and strengthening business fundamentals to sustain growth momentum.

Davuluri further noted that the company is simultaneously building the foundation for its next phase of growth through strategic investments in peptide manufacturing and a new R&D centre, both of which are progressing as planned. He also highlighted that Neuland’s business development strategy remains aligned with these investments and is focused on attracting high-quality projects that can deliver sustainable long-term growth.

Share Price Performance & Technical Indicators

Neuland Laboratories shares have delivered a strong rally, gaining nearly 20% over the past one month. The stock has also emerged as a multibagger in the long term, skyrocketing around 572% in the last three years. The company currently commands a market capitalisation of approximately Rs 22,366 crore, while its 52-week high stands at Rs 19,747.

On the technical front, the stock’s Relative Strength Index (RSI-14) is at 67.9, suggesting strong momentum. Typically, an RSI below 30 is considered oversold, while a reading above 70 signals overbought conditions. The trend remains firmly bullish as Neuland Laboratories is trading above all 8 out of 8 key Simple Moving Averages (SMAs), reflecting sustained buying strength and positive market sentiment.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)